ENANTA PHARMACEUTICALS INC
About ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $65.3M
- Net income
- -$81.9M
- Total assets
- $280.7M
- Market cap
- $328.0M
- Operating margin
- -130.7%
- Net margin
- -125.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $65.3M
- Operating expenses
- $150.7M
- Operating income
- -$85.3M
- Income tax
- -$1.7M
- Net income
- -$81.9M
- EPS (basic)
- $-3.84
- EPS (diluted)
- $-3.84
Balance sheet
- Total assets
- $280.7M
- Current assets
- $204.3M
- Total liabilities
- $216.0M
- Current liabilities
- $48.6M
- Shareholders’ equity
- $64.7M
Cash flow
- Operating cash flow
- -$19.3M
- Investing cash flow
- $40.3M
- Financing cash flow
- -$26.6M
- Net cash flow
- -$5.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $328.0M
- EPS (diluted)
- $-3.84
- Shares outstanding
- 28.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 21, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $81.9M in FY2025.
- Revenue declined 47% from FY2020 to FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ENANTA PHARMACEUTICALS INC.
Write a review
News about ENANTA PHARMACEUTICALS INC
News & sentiment via Polygon.io
